Coral Laboratories Limited has issued a formal postal ballot notice to shareholders seeking approval for the re-appointment of Mr. Malay Doshi as Independent Director. The notice, sent on April 6, 2026, initiates the e-voting process for the special resolution approved by the board during its April 2, 2026 meeting.

E-Voting Schedule and Process

The company has engaged National Securities Depository Limited (NSDL) to facilitate remote e-voting for all shareholders. The voting process provides a comprehensive digital platform for shareholder participation.

Independent Director Re-appointment Details

The postal ballot seeks shareholder approval for Mr. Malay Doshi's second consecutive term as Independent Director. The board's recommendation follows performance evaluation and the Nomination and Remuneration Committee's assessment.

Professional Background and Expertise

Mr. Doshi serves as the owner of Malay Doshi & Associates, a proprietary firm established in April 2012. His professional services span multiple domains including audit, tax consultancy, and regulatory compliance.

Shareholder Voting Guidelines

The postal ballot notice provides detailed instructions for different categories of shareholders, including those holding securities in demat mode with NSDL or CDSL, and those with physical share certificates. Shareholders must have their names in the Register of Members as of the April 3, 2026 cut-off date to be eligible for voting.

The resolution requires approval as a Special Resolution, and if passed by the requisite majority, will be deemed effective from May 6, 2026. The company has confirmed that all regulatory disclosures comply with SEBI Listing Regulations and Companies Act, 2013 requirements.

Coral laboratories has successfully completed the capacity expansion of its General Pharmaceuticals Formulation unit at its Dehradun plant. The company announced on March 23, 2026, that the expansion project has been completed and commercial operations have commenced at the enhanced facility.

Capacity Expansion Details

The expansion project focused on the General Pharmaceuticals Formulation (Ointment) unit at the Dehradun manufacturing facility. The key parameters of the completed expansion include:

Project Timeline and Implementation

The capacity expansion project was initially announced by the company on October 13, 2025. The successful completion of the project within approximately five months demonstrates the company's execution capabilities in scaling its manufacturing operations.

Commercial Operations Commencement

Coral Laboratories confirmed that the expanded facility has commenced commercial operations, indicating that the enhanced production capacity is now contributing to the company's manufacturing output. The operational commencement marks the successful transition from the expansion phase to active production at the increased capacity levels.

Strategic Manufacturing Enhancement

The completion of this capacity expansion represents a significant enhancement to Coral Laboratories' manufacturing capabilities in the pharmaceutical formulation segment. The expanded ointment production capacity of 360,000 kgs positions the company to meet increased market demand and strengthen its presence in the General Pharmaceuticals Formulation category.